Dave, it does indeed look interesting.

One good thing is that bexarotene has FDA approval as a cancer chemotherapeutic which means that the basic (Phase 1 clinical trials) checking will have been done.

So, with luck and more work (if it checks out) it might be possible to introduce it as an AD treatment fairly soon.